These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 20368727)

  • 1. Biomarkers and surrogate end points--the challenge of statistical validation.
    Buyse M; Sargent DJ; Grothey A; Matheson A; de Gramont A
    Nat Rev Clin Oncol; 2010 Jun; 7(6):309-17. PubMed ID: 20368727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.
    Prasad V; Kim C; Burotto M; Vandross A
    JAMA Intern Med; 2015 Aug; 175(8):1389-98. PubMed ID: 26098871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers.
    Sargent DJ; Mandrekar SJ
    Clin Trials; 2013 Oct; 10(5):647-52. PubMed ID: 23983158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.
    Korn EL; Sachs MC; McShane LM
    Ann Oncol; 2016 Jan; 27(1):10-5. PubMed ID: 26489443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology.
    Haslam A; Hey SP; Gill J; Prasad V
    Eur J Cancer; 2019 Jan; 106():196-211. PubMed ID: 30528804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation.
    Burzykowski T; Buyse M
    Pharm Stat; 2006; 5(3):173-86. PubMed ID: 17080751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
    Powers JH
    Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.
    Saad ED; Katz A; Hoff PM; Buyse M
    Ann Oncol; 2010 Jan; 21(1):7-12. PubMed ID: 19901012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogate end points in secondary analyses of cardiovascular trials.
    Buhr KA
    Prog Cardiovasc Dis; 2012; 54(4):343-50. PubMed ID: 22226002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation of the results of clinical trials: surrogate end points and composite end points.
    Gensini GF; Conti AA
    Minerva Med; 2004 Feb; 95(1):71-5. PubMed ID: 15041928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.
    Inker LA; Heerspink HJL; Tighiouart H; Levey AS; Coresh J; Gansevoort RT; Simon AL; Ying J; Beck GJ; Wanner C; Floege J; Li PK; Perkovic V; Vonesh EF; Greene T
    J Am Soc Nephrol; 2019 Sep; 30(9):1735-1745. PubMed ID: 31292197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of surrogate end points in the evaluation of drugs for heart failure.
    Lipicky RJ; Packer M
    J Am Coll Cardiol; 1993 Oct; 22(4 Suppl A):179A-184A. PubMed ID: 8376690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.
    Buyse M; Molenberghs G; Paoletti X; Oba K; Alonso A; Van der Elst W; Burzykowski T
    Biom J; 2016 Jan; 58(1):104-32. PubMed ID: 25682941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.
    Michiels S; Saad ED; Buyse M
    Drugs; 2017 May; 77(7):713-719. PubMed ID: 28337673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.
    Badve SV; Palmer SC; Hawley CM; Pascoe EM; Strippoli GF; Johnson DW
    Nephrol Dial Transplant; 2016 Sep; 31(9):1425-36. PubMed ID: 26163881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative clinical end points in rectal cancer--are we getting closer?
    Glynne-Jones R; Mawdsley S; Pearce T; Buyse M
    Ann Oncol; 2006 Aug; 17(8):1239-48. PubMed ID: 16873440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials.
    Dai JY; Hughes JP
    Biostatistics; 2012 Sep; 13(4):609-24. PubMed ID: 22394448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials.
    Baker SG
    Stat Med; 2018 Feb; 37(4):507-518. PubMed ID: 29164641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.